Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical
antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it …

Cognitive function is markedly impaired in most patients with schizophrenia. Antecedents of
this impairment are evident in childhood. The cognitive disability is nearly fully developed at …

Treatment-resistant schizophrenia is the object of intense interest because of recent
developments in its treatment and aetiology. The actual definition of treatment-resistant …

Cognitive impairment is a core feature of schizophrenia and a major impediment to social
and vocational rehabilitation. A number of studies have claimed cognitive benefits from …

OBJECTIVE: Novel antipsychotic medications have been reported to have beneficial effects
on cognitive functioning in patients with schizophrenia. However, these effects have been …

Cognition is what enables humans to function in everyday life: personal, social, and
occupational. The ability to attend to things in a selective and focused way, to concentrate …

Reducing the risk of violent and aggressive behaviour in patients with schizophrenia
remains a clinical priority. There is emerging evidence to suggest that the second …

Abstract Objective: On April 23, 2004, a joint meeting of the FDA, NIMH, MATRICS
investigators, and experts from academia and the pharmaceutical industry was convened to …

OBJECTIVE: Outcomes for negative symptoms over a one-year period were examined in
two groups of patients, one receiving psychoeducational multiple-family group treatment and …